ITGI completes development of pericardium-covered stent

Israel's ITGI Medical has completed development of its next-generation AneuGraftDX pericardium-covered stent, which has received EU CE Mark certification for sales. ITGI's share price rose 4.9 percent on the news, according to Globes.

As Globes reports, the new stents have a narrower diameter than their predecessors. They're suitable for insertion through the radial artery, which is narrower than the femoral artery. Furthermore, they are easier to sterilize and don't require prior preparation for catheterization procedures. The company thinks these stents could be cheaper to produce than currently available ones.

ITGI specializes in the research and development, design, manufacture and distribution of heterologous tissue-covered stents for cardiovascular and neurovascular interventions, according to the ITGI website. Back in 2007, the company had its initial public offering on the Tel Aviv stock exchange. The IPO allowed the company to develop and mass manufacture a pericardium-covered stent.

Late last month, the company reported that six months after the stent was implanted, the artery was still open and the blood was flowing normally, according to Globes.

- get more from Globes

Suggested Articles

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.